Wellington Management Group LLP Increases Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Wellington Management Group LLP grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,595,715 shares of the medical research company's stock after purchasing an additional 167,763 shares during the period. Wellington Management Group LLP owned about 0.42% of Thermo Fisher Scientific worth $794,028,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TMO. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the first quarter worth about $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Navigoe LLC bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday. They issued an "outperform" rating for the company. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Down 0.2%

TMO stock opened at $488.15 on Tuesday. The company has a market capitalization of $184.33 billion, a PE ratio of 28.23, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company's 50 day moving average price is $436.43 and its two-hundred day moving average price is $458.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the firm earned $5.37 earnings per share. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.